Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.39 Billion JPY | -231.25% |
| 2022 | 5.01 Billion JPY | -5.41% |
| 2021 | 8.18 Billion JPY | 49.35% |
| 2020 | 2.2 Billion JPY | 41.1% |
| 2019 | 2.44 Billion JPY | 141.72% |
| 2018 | -6.41 Billion JPY | -320.25% |
| 2017 | -1.43 Billion JPY | -109.83% |
| 2016 | 13.05 Billion JPY | 627.97% |
| 2015 | 1.85 Billion JPY | 29.66% |
| 2014 | 1.45 Billion JPY | 91.77% |
| 2013 | 758.2 Million JPY | 28.94% |
| 2012 | 1 Billion JPY | 277.15% |
| 2011 | -355 Million JPY | 2.58% |
| 2010 | -271.35 Million JPY | -35.14% |
| 2009 | -253.55 Million JPY | 87.69% |
| 2008 | -2.05 Billion JPY | 46.43% |
| 2007 | -4.62 Billion JPY | 18.88% |
| 2006 | -5.02 Billion JPY | -45.93% |
| 2005 | -3.43 Billion JPY | -100.04% |
| 2004 | -1.74 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 116 Million JPY | 151.79% |
| 2024 Q3 | 2.05 Billion JPY | 144.23% |
| 2024 Q1 | -2.41 Billion JPY | -700.0% |
| 2023 Q2 | -1.33 Billion JPY | 1.26% |
| 2023 FY | - JPY | -231.25% |
| 2023 Q3 | -2.66 Billion JPY | -99.25% |
| 2023 Q1 | -1.35 Billion JPY | -128.43% |
| 2023 Q4 | -500 Million JPY | 81.23% |
| 2022 FY | - JPY | -5.41% |
| 2022 Q4 | 4.76 Billion JPY | 35.48% |
| 2022 Q3 | 3.51 Billion JPY | 376.34% |
| 2022 Q2 | -1.27 Billion JPY | 35.95% |
| 2022 Q1 | -1.98 Billion JPY | -124.91% |
| 2021 FY | - JPY | 49.35% |
| 2021 Q4 | 7.97 Billion JPY | 515.42% |
| 2021 Q3 | -1.91 Billion JPY | -2232.22% |
| 2021 Q1 | -841 Million JPY | -123.86% |
| 2021 Q2 | 90 Million JPY | 110.7% |
| 2020 FY | - JPY | 41.1% |
| 2020 Q1 | 47 Million JPY | -12.96% |
| 2020 Q2 | -152 Million JPY | -423.4% |
| 2020 Q3 | 389 Million JPY | 355.92% |
| 2020 Q4 | 3.52 Billion JPY | 806.17% |
| 2019 Q2 | 402 Million JPY | -75.53% |
| 2019 Q1 | 1.64 Billion JPY | 177.61% |
| 2019 FY | - JPY | 141.72% |
| 2019 Q3 | 1.3 Billion JPY | 225.37% |
| 2019 Q4 | 54 Million JPY | -95.87% |
| 2018 Q3 | -1.15 Billion JPY | 24.0% |
| 2018 FY | - JPY | -320.25% |
| 2018 Q2 | -1.52 Billion JPY | 23.57% |
| 2018 Q1 | -1.99 Billion JPY | -93.77% |
| 2018 Q4 | -2.11 Billion JPY | -83.13% |
| 2017 Q1 | -1.08 Billion JPY | -198.1% |
| 2017 FY | - JPY | -109.83% |
| 2017 Q4 | -1.02 Billion JPY | -214.37% |
| 2017 Q3 | 898 Million JPY | 4.3% |
| 2017 Q2 | 861 Million JPY | 179.28% |
| 2016 FY | - JPY | 627.97% |
| 2016 Q3 | 2 Million JPY | -99.99% |
| 2016 Q4 | 1.1 Billion JPY | 55250.0% |
| 2016 Q2 | 13.95 Billion JPY | 1006.5% |
| 2016 Q1 | -1.53 Billion JPY | -138.28% |
| 2015 FY | - JPY | 29.66% |
| 2015 Q1 | 1.51 Billion JPY | 1296.82% |
| 2015 Q2 | -759 Million JPY | -150.15% |
| 2015 Q3 | 546 Million JPY | 171.94% |
| 2015 Q4 | 4.02 Billion JPY | 636.26% |
| 2014 Q4 | 108.34 Million JPY | 204532.08% |
| 2014 Q1 | 1.27 Billion JPY | 375.64% |
| 2014 FY | - JPY | 91.77% |
| 2014 Q2 | -72.16 Million JPY | -105.68% |
| 2014 Q3 | -53 Thousand JPY | 99.93% |
| 2013 Q4 | -461.18 Million JPY | -131.62% |
| 2013 FY | - JPY | 28.94% |
| 2013 Q2 | -671.25 Million JPY | -8.0% |
| 2013 Q1 | -621.51 Million JPY | -352.11% |
| 2013 Q3 | 1.45 Billion JPY | 317.28% |
| 2012 Q1 | -659.99 Million JPY | -7.18% |
| 2012 FY | - JPY | 277.15% |
| 2012 Q2 | -613.96 Million JPY | 6.97% |
| 2012 Q4 | -137.47 Million JPY | -134.53% |
| 2012 Q3 | 398.15 Million JPY | 164.85% |
| 2011 Q4 | -615.76 Million JPY | -286.2% |
| 2011 Q3 | -159.44 Million JPY | 69.71% |
| 2011 Q2 | -526.31 Million JPY | -71.39% |
| 2011 Q1 | -307.07 Million JPY | -2.34% |
| 2011 FY | - JPY | 2.58% |
| 2010 Q1 | -310.05 Million JPY | -67.55% |
| 2010 Q2 | 460.21 Million JPY | 248.43% |
| 2010 Q3 | -215.66 Million JPY | -146.86% |
| 2010 FY | - JPY | -35.14% |
| 2010 Q4 | -300.05 Million JPY | -39.13% |
| 2009 Q2 | 407.14 Million JPY | 349.58% |
| 2009 Q3 | -180.34 Million JPY | -144.3% |
| 2009 Q4 | -185.05 Million JPY | -2.61% |
| 2009 FY | - JPY | 87.69% |
| 2009 Q1 | -163.13 Million JPY | 76.31% |
| 2008 Q4 | -688.68 Million JPY | 34.97% |
| 2008 FY | - JPY | 46.43% |
| 2008 Q3 | -1.05 Billion JPY | 0.0% |
| 2007 FY | - JPY | 18.88% |
| 2006 FY | - JPY | -45.93% |
| 2005 FY | - JPY | -100.04% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 872.256% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -1415.779% |
| GNI Group Ltd. | 14.48 Billion JPY | 151.067% |
| Linical Co., Ltd. | 1.24 Billion JPY | 693.233% |
| Trans Genic Inc. | 240.95 Million JPY | 3170.736% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | -445.707% |
| Soiken Holdings Inc. | -583.2 Million JPY | -1168.677% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -1126.846% |
| AnGes, Inc. | -8.86 Billion JPY | 16.49% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -475.577% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 5875.641% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -757.358% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -577.699% |
| CanBas Co., Ltd. | 53.65 Million JPY | 13890.982% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -853.982% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -6518.009% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -510.611% |
| Kidswell Bio Corporation | -1.38 Billion JPY | -435.841% |
| PeptiDream Inc. | 7.37 Billion JPY | 200.311% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | -283.429% |
| Ribomic Inc. | -1.01 Billion JPY | -630.747% |
| SanBio Company Limited | -4.52 Billion JPY | -63.514% |
| Healios K.K. | -3 Billion JPY | -146.059% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -534.679% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -431.13% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -427.746% |
| StemRIM | -2.03 Billion JPY | -264.124% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 666.348% |
| FunPep Company Limited | -952 Million JPY | -677.206% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -732.506% |
| Stella Pharma Corporation | -723.85 Million JPY | -922.167% |
| TMS Co., Ltd. | -937 Million JPY | -689.648% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -854.228% |
| Cuorips Inc. | -518 Million JPY | -1328.378% |
| K Pharma,Inc. | 366.05 Million JPY | 2121.264% |
| Takara Bio Inc. | 8.02 Billion JPY | 192.211% |
| ReproCELL Incorporated | 8.24 Million JPY | 89839.236% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 8513.883% |
| StemCell Institute Inc. | 534.35 Million JPY | 1484.663% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 3122.294% |
| CellSeed Inc. | -836.51 Million JPY | -784.502% |